Home > Rheumatology > EULAR 2020 > Ankylosing Spondylitis > Certolizumab pegol reduces acute anterior uveitis in axial spondyloarthritis

Certolizumab pegol reduces acute anterior uveitis in axial spondyloarthritis

Presented By
Prof. Irene van der Horst-Bruinsma, Amsterdam University Medical Center, the Netherlands
Conference
EULAR 2020
Trial
C-VIEW
Results from the ongoing, multicentre, open-label, phase 4 C-VIEW trial show that certolizumab pegol significantly reduces acute anterior uveitis (AAU) flare rate and axial spondyloarthritis (axSpA) disease activity [1]. AAU is an inflammation of the anterior uveal tract characterised by blurred vision, photophobia, and pain [2]. It is reported in up to 40% of axSpA patients, which makes it the most common extra-articular manifestation in axSpA patients [3]. Previous studies have shown that TNF inhibitor (TNFi) monoclonal antibodies may reduce AAU flare incidence in patients with radiographic axSpA, but data in non-radiographic axSpA is scarce [4-6]. Prof. Irene van der Horst-Bruinsma (Amsterdam University Medical Center, the Netherlands) presented the results of the phase 4 C-VIEW trial that analysed the impact of certolizu...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on